Table 3.
Characteristic | Univariate P value |
Multivariate P value |
Multivariate Hazard Ratio |
|
---|---|---|---|---|
Age | ≥70 | 0.856 | ||
Sex | male | 0.013 | 0.214 | 1.54 (95% CI; 0.78–3.30) |
Performance status | ≥2 | 0.994 | ||
Brinkman index | ≥1000 | 0.019 | 0.007 | 2.75 (95% CI; 1.32–5.77) |
Neurological dysfunction | 0.488 | |||
Neurocognitive disorder | 0.775 | |||
Histology | AC | 0.098 | ||
Number of brain metastases | ≥3 | 0.115 | ||
Prior WBRT | 0.098 | |||
Pulmonary metastases | <0.001 | 0.009 | 3.54 (95% CI; 1.39–8.58) | |
Liver metastases | 0.008 | 0.619 | 1.28 (95% CI; 0.45–3.18) | |
Bone metastases | 0.061 | |||
Adrenal metastases | 0.394 | |||
Uncontrolled primary disease | <0.001 | 0.002 | 3.04 (95% CI; 1.54–6.03) | |
LC | 0.163 | |||
DBF | 0.373 |
AC = adenocarcinoma, WBRT = whole brain radiotherapy, CI = confidence interval, LC = local control, DBF = distant brain failure.